Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 29, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Feb 14, 2022
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection… Nov 16, 2021
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Oct 26, 2021
Revive Therapeutics: Remains Discounted To Peers As Oral COVID Therapeutics Race Heats Up Aug 11, 2021
